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ABSTRACT
Spyl is a cell cycle activator, known to mediate cell cycle progression through an 
atypical activation of the cyclin dependent kinases. To understand the development and 
progression of breast cancer it is essential to elucidate the mechanisms and interactions of 
normal regulators of breast development. This study demonstrates that endogenous Spyl 
protein and mRNA levels are tightly regulated during normal mammary gland 
development; being expressed during proliferative stages and downregulated at the onset 
of lactation. This appears to be regulated, in part, through the oncogene c-Myc and the 
MAPK signaling pathway. Importantly, we show that aberrant expression of the Spyl 
protein prevents normal differentiation and results in disrupted morphology of the gland 
as well as tumorigenesis. Collectively this work has revealed a novel molecular 
mechanism regulating normal developmental processes in the breast and has provided 
evidence that the Spyl protein may also be implicated in the development of breast 
cancer.
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CHAPTER I 
INTRODUCTION 
Regulation of the Cell Division Cycle; an Overview
The cell division cycle is a delicate and highly controlled process that functions to 
control cell division and growth, as well as maintain the integrity of the cell’s genetic 
material. Progression through the cell cycle involves four phases: Gapl (Gl), DNA 
Synthesis (S), Gap2 (G2) and Mitosis (M). Rapid cell growth, duplication of the 
organelles and drastic changes in cytosolic volume happen in Gl phase. During late Gl 
the cell assesses the available nutrients, growth conditions and its DNA integrity and 
decides to either exit or commit to the cell cycle; this is a point referred to as the 
restriction point, or the Gl/S checkpoint. If the cell exits the cell cycle, it enters a 
stationary phase called quiescence (GO). A quiescent cell remains metabolically active, 
and maintains the ability to re-enter the cell cycle when the growing conditions become 
favourable. Following successful movement through the restriction point, the cell 
replicates the genome in S phase then moves into the second preparatory phase, G2. Here 
the cell prepares for entry into M phase by turning on the necessary regulatory proteins 
required to initiate mitotic events as well as to monitor DNA integrity and repair any 
DNA damage before entering mitosis (Pardee 1989). During M phase replicated DNA 
molecules partition into two nuclei, following this event, the entire dividing cell splits in 
two daughter cells. The two daughter cells resulting from mitosis possess a genetic 
content identical to each other and to the mother cell from which they arose. All these 
processes involved in the cell division cycle are tightly regulated at the molecular level 
via many different signaling pathways (Pardee 1989).
1
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Cell Cycle Regulation by Cvclin-CDK Complexes
Cell cycle progression is regulated by the activity of a family of serine/threonine 
protein kinases, called cyclin dependent kinases (CDKs). CDKs are considered the 
engines that drive the cell cycle through its various stages. To date, eleven human CDKs 
have been identified; these proteins function to phosphorylate many structural and 
regulatory proteins required for movement through the cell cycle and successful cell 
division (Malumbres and Barbacid 2005).
CDK activity is tightly controlled by specific protein-protein interactions; one 
important level of regulation is through the binding of the CDK regulatory subunit, 
referred to as cyclin. Cyclin protein concentrations vary from one stage of the cell cycle 
to another; being transcriptionally upregulated at specific points and degraded in a 
regulatory fashion via ubiquitin mediated proteolysis. Cyclins contain a conserved 100 
amino acid region, called cyclin box. The cyclin box is responsible for interaction with 
the CDK (Sherr 1994; Morgan 1995; Sherr and Roberts 1999). When cyclins are present 
in the cell, they bind to the catalytic subunit of the CDK. This binding causes a major 
conformational change within the CDK catalytic subunit resulting in the movement of a 
flexible loop of the CDK (the T-loop) away from the enzyme’s active site. This new 
conformation allows the CDK to become phosphorylated on a threonine residue (Thrl60 
or Thrl61) within the T-loop of the CDK kinase domain by cyclin activating kinase 
(CAK). It is now well established that, in order to be in a fully active conformation, a 
CDK must also be dephosphorylated on threonine and tyrosine residues (Thrl4 and 
Tyrl5) by the CDC25 phosphatases (Jeffrey et al. 1995). Once activated, some Cyclin- 
CDK complexes undergo relocalization within the cell. For example, Cyclin B-CDK1 is
2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4
Cyclin D-CDK4/6 phosphorylate a number of substrates initiating movement through the 
cell cycle; many of these promote the transcriptional regulation of the Gl/S phase 
cyclins, Cyclin E, and Cyclin A. Cyclins E and A associate with their respective CDK 
partner (CDK2) to promote initiation of replication. Activation of Cyclin E-CDK2 is 
essential for DNA synthesis at the Gl/S transition. p27 interaction with Cyclin E-CDK2 
prevents premature entry into S phase (Nakayama et al. 2001). Normally, p27 protein 
levels are high during GO and Gl phases of the cell cycle, resulting in Cyclin-CDK 
inhibition. p27 has been found to associate with Cyclin A-CDK2, Cyclin E-CDK2 and 
Cyclin D-CDK4,6 (Slingerland and Pagano 2000). Importantly, Cyclin D-CDK4 also 
forms a trimeric complex with p27, so less p27 is available to inhibit Cyclin E-CDK2; 
and hence this interaction in fact promotes cell cycle movement rather than inhibiting it. 
Interestingly, one of the substrates that Cyclin E-CDK2 phosphorylates, is p27. This 
phosphorylation occurs at amino acid Thrl87 within p27 and functions to target the CKI 
for degradation via the SCFSkp2 (Skp, Cullin, F-box containing complex) ubiquitin ligase 
pathway (Pagano et al. 1995; Sheaff et al. 1997; Vlach et al. 1997; Carrano et al. 1999; 
Montagnoli et al. 1999; Sutterluty et al. 1999; Tsvetkov et al. 1999). Decreased protein 
levels of p27 allows progression into S phase. In general, the SCF complex acts through 
out the cell cycle and mediates the degradation of other CKIs, as well as Gl cyclins and 
cell cycle proteins.
Molecular Controls over the G2/M Transition and Progression through Mitosis 
The G2/M transition and M phase progression are primarily regulated via 
activation of both Cyclin A-CDK1 and Cyclin B-CDK1 complexes. These cyclins are 
synthesized and associate with CDK1 in late S phase and early G2 respectively, but the
4
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complexes remain inactive due to the inhibitory phosphorylation of CDK1 on the key 
threonine and tyrosine residues (Thrl4 and Tyrl5) by Mytl. Phosphorylation of CDK1 
on Thrl61 by CAK, and dephosphorylation by the CDC25 phosphatase family occurs at 
early G2 for Cyclin A-CDK1 and in late G2 for Cyclin B-CDK1. The active Cyclin- 
CDK1 complex phosphorylates a diverse range of proteins responsible for G2/M 
transition, M phase entry and progression through M phase; such as cytoskeletal proteins, 
histones and proteins of the nuclear envelope. By the end of mitosis, the cyclin separates 
from CDK1, and a phosphatase removes the phosphate group from Thrl61. The free 
cyclin becomes degraded via the anaphase promoting complex or APC complex. APC 
acts in mitosis and degrades mitotic proteins, including mitotic cyclins. Destruction of 
cyclins A and B is a key factor in the inactivation of CDK1 and the transition of the cell 
from mitosis back into Gl (Coleman and Dunphy 1994).
5
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CHAPTER II 
REVIEW OF LITERATURE 
Isolation and Characterization of Xenopus Speedy
Xenopus Speedy or X-Spyl was first identified in a genetic screen utilizing a 
Xenopus Laevis ovary cDNA library to isolate novel genes which conferred resistance to 
UV radiation using a radl-deficient strain of the fission yeast, Schizosaccharomyces 
pombe (Lenormand et al. 1999). radl is a cell cycle checkpoint gene which arrests the 
cell at G2/M in the presence of DNA damage or in the absence of complete DNA 
replication (al-Khodairy and Carr 1992). Loss of radl function causes cell death 
following DNA damage (Hartwell and Weinert 1989). This initial discovery prompted 
researchers to believe that Spyl was involved in the DNA damage response. Immediately 
following the publication of X-Spyl, another group reported the isolation of two isoforms 
of a gene they entitled, Xenopus RINGO or X-RINGO (Rapid Inducer of G2/M Ooctye 
Maturation). X-RINGO was identified using an expression cloning strategy to identify 
novel proteins involved in G2/M progression in Xenopus oocytes. The two isoforms of X- 
RINGO are 88% identical to one another and one of the isoforms shows 99% identity 
with X-Spyl (Porter et al. 2002). Throughout this thesis the latter form of X-RINGO will 
be referred as X-Spyl.
Xenopus oocytes are naturally arrested in late G2 and G2/M boundary of the first 
meiotic division. Progesterone stimulation is known to overcome oocytes arrest and 
promote progression of the oocytes through meiosis. This process, known as meiotic 
maturation, results in germinal vesicle break down (GVBD) and activation of the Cyclin 
B1-CDK1 complex, also referred to as the maturation promoting factor (MPF). Oocytes
6
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enter into meiosis I, then arrest again at metaphase of meiosis II until fertilization (Sagata 
1997). X-Spyl expression in oocytes, either as synthetic mRNA or recombinant protein, 
induces MPF activation and GVBD in the absence of progesterone. Furthermore, 
introducing antisense oligonucleotides against X-Spyl into oocytes is able to delay 
progesterone-induced oocyte maturation. This demonstrates that X-Spyl expression in 
G2 arrested oocytes is required for progesterone-induced oocyte meiotic maturation 
(Ferby et al. 1999). Also, X-Spyl over-expression induces oocyte meiotic maturation 
faster than progesterone (Ferby et al. 1999; Lenormand et al. 1999). X-Spyl deletion 
mutants show that amino acids 54-218, a highly conserved central region coined the 
“Spyl/RINGO box”, is essential for induction of oocyte maturation; whereas the amino 
and carboxy termini of the protein are dispensable for this function (Porter et al. 2002).
Previous studies have suggested that progesterone-induced maturation can be 
activated by the mos proto-oncogene, as injection of specific antisense mos 
oligonucleotide into oocytes blocks progesterone-induced GVBD (Sagata 1997). 
Hormonal activation of prophase arrested oocytes leads to activation of the mitogen 
activated protein kinase pathway (MAPK pathway) (Nebreda and Hunt 1993). It has been 
proven that progesterone induces oocytes by stimulating the translation of Mos protein, 
which is a MAP kinase kinase kinase (MAPKKK). Mos in turn leads to activation of the 
MAP kinase kinase, MEK (Sagata 1997). Interestingly, antisense mos oligonucleotides 
failed to block Spyl-induced GVBD, indicating that mos is not required for Spyl- 
induced maturation (Lenormand et al. 1999). Further experiments have shown that, when 
activation of MEK was blocked using a MEK antibody, X-Spyl-induced maturation was 
inhibited too. Furthermore, recombinant X-Spyl can trigger GVBD and MPF activation
7
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even in the presence of the MEK protein synthesis inhibitor PD98059. This information 
together, suggests that X-Spyl is under regulation of MEK through MAPK pathway 
(Ferby et al. 1999; Lenormand et al. 1999). Further studies suggest that X-Spyl induces 
rapid meiotic maturation through the MAPK pathways and this in turn causes rapid 
activation of MPF through a premature activation of CDK2 (Lenormand et al. 1999). 
Although X-Spyl does not show amino acid sequence homology to cyclins, studies show 
that Spyl both binds to and activates CDK1 and CDK2 independent of cyclin binding 
(Ferby et al. 1999; Lenormand et al. 1999; Karaiskou et al. 2001). Interestingly, both X- 
Spyl and RINGO bind and activate CDK2 in a p21-independent manner (Ferby et al. 
1999; Lenormand et al. 1999). Also, it has been reported that the activation of CDK2 
does not rely on the phosphorylation of the CDK at residue Thrl61 (Karaiskou et al. 
2001). Collectively this demonstrates that Spyl is capable of activating CDKs utilizing a 
novel mechanism.
Regulation of Xenopus -Spyl Protein Levels
Endogenous X-Spyl expression is tightly regulated during the meiotic cell cycle. 
At the onset of meiosis I entry, X-Spyl protein levels are increased transiently and then 
decrease significantly between meiosis I and meiosis II. This tight regulation is via the 
ubiquitin proteasome system (UPS) at two different levels, processing and degradation. 
X-Spyl has been shown to be processed into X-RINGOSp (for X-RINGO small and 
processed) by the joint activity of two kinases that are active in G2-arrested oocytes 
named, protein kinase A (PKA), glycogen synthase kinase-3P (GSK-3P), and the 
ubiquitin ligase pTrCP (SCFpTrCP). The DSGXXS motif is considered to be the pTrCP 
recognition motif; however certain pTrCP substrates such as CDC25A or Weel A contain
8
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several functional motifs involved in (3TrCP recognition (Watanabe et al. 2004; Kanemori 
et al. 2005; Watanabe et al. 2005). In the case of X-Spyl, a canonical DSGXXS motif 
acts as the major PTrCP recognition motif, however phosphorylation by PKA and GSK- 
3p create additional recognition sites. X-Spyl is also degraded by the UPS after GVBD. 
This event requires the activity of mitotic kinases and the RING-finger ubiquitin ligase 
Siah-2. Recognition of the substrates by Siah-2 ubiquitin ligase does not require specific 
phospohrylation of the substrates. However, X-Spyl phosphorylation on Ser 243 is 
necessary for X-Spyl recognition by Siah-2 and X-Spyl downregulation after meiosis I. 
Ser243 residue on X-Spyl is a potential target for CDK2 phosphorylation. Maybe CDK2, 
which accumulates during oocyte maturation, regulates X-Spyl protein levels via a 
negative feed back loop. Interestingly, failure to initiate X-Spyl down regulation causes 
DNA synthesis during the meiosis I- meiosis II transition (Gutierrez et al. 2006). This 
data implicates X-Spyl in altering DNA integrity during early stages of development, 
which may implicate Spyl in the early initiation of carcinogenesis.
Regulation of Xenopus -Spyl RNA Levels
As is the case for many proteins involved in Xenopus oocyte maturation, X-Spyl 
mRNA has been shown to remain dormant in the resting oocyte and to be rapidly 
translated soon after the induction of meiotic maturation. It is possible that in addition to 
regulation by protein processing and degradation, de-repression of X-Spyl mRNA 
translation contributes to X-Spyl accumulation during Xenopus oocyte maturation 
(Padmanabhan and Richter 2006). One of the highly regulated events that occur during 
vertebrate oocyte maturation is the maternal mRNA translation of early genes such as, 
MAPK, MPF and Mos. For instance, Mos and cyclin mRNA translation is regulated by
9
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cytoplasmic polyadenylation, which requires the cytoplasmic polyadenylation element 
(CPE) in the 3’UTR of these genes. CPEB, cytoplasmic polyadenylation element binding 
protein, is a sequence specific RNA binding protein. It binds to CPE and regulates the 
translation of maternal mRNA via polyadenylation of the maternal mRNA. 
Polyadenylation-stimulatory activity of CPEB is controlled by Aurora A-catalyzed S I74 
phosphorylation. It also interacts with various factors to stimulate polyadenylation. In 
addition to polyadenylation, CDK activity is also necessary for the activation of the Mos- 
MAPK and MPF pathways during meiotic maturation. There is a possibility that a small 
amount of Cyclin B1 mRNA translates soon after progesterone induction. The 
synthesized Cyclin B protein induces CDK activity that, in turn stimulates CPEB- 
mediated polyadenylation. It has been demonstrated that over expression of X-Spyl in 
oocytes rapidly induces Mos synthesis, as well as MAPK and MPF activation and X- 
Spyl binds and activates CDK1 and CDK2 (Littlewood et al. 1995; Ferby et al. 1999). 
This information suggests that, X-Spyl may associate with free CDK1 in oocytes and 
activate MPF. Also, it is possible that the translation of X-Spyl activates CPEB. Studies 
determine not only the necessity of X-Spyl protein for CPEB-mediated polyadelynation 
during meiotic maturation of oocytes, but also the mechanism by which X-Spyl mRNA 
translation is controlled. X-Spyl synthesis precedes and it is required for CPEB 
phosphorylation and other downstream effects such as Mos mRNA polyadenylation and 
translation. In immature oocytes, a region of the 3’UTR that includes Pumilio 2-Binding 
Elements (PBEs) represses X-Spyl mRNA translation. One of the proteins that associate 
with PEB is Pum2. Oocyte injection with either Pum2 antibody or dominant negative 
form of Pum2 protein stimulates X-Spyl synthesis and oocyte maturation. Progesterone
10
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treatment of oocytes dissociates Pum2 from X-Spyl mRNA, which in turn results in X- 
Spyl mRNA translation. It is suggested that Pum2-mediated translation of X-Spyl 
mRNA is required for CPEB activation.
Isolation and Characterization of Human Speedy (Spyl)
A database search for other Spyl homologs yielded a human EST clone from a 
testis cDNA library with 63% homology over a 170 bp region of X-Spyl. Using PCR 
based serial dilution cloning method; the first full length human homologue of Speedy 
gene was isolated from a human testis cDNA library. The human Spyl (Spyl) cDNA 
clone is a 1300 bp sequence, and encodes for a polypeptide containing 286 amino acids. 
Spyl shows an overall 40% homology to X-Spyl, including a highly conserved 150 
amino acid region with 70% homology (Porter et al. 2002). Spyl mRNA microinjection 
in Xenopus oocytes induced maturation in the absence of progestrone, albeit less 
efficiently than X-Spyl (Porter et al. 2002). Spyl mRNA is expressed in multiple human 
tissues and immortalized cell lines (Porter et al. 2002; Cheng et al. 2005b). Further 
investigation has demonstrated that Spyl is regulated in a cell cycle-dependent manner 
and it is highly expressed at Gl/S transition. Spyl is localized in nucleus; it interacts with 
CDK2 independent of cyclin binding and stimulates CDK kinase activity in mammalian 
cells. Overexpression of Spyl increases cell proliferation. More precisely, cells 
overexperessing Spyl show significant increases in both DNA replication events and 
mitochondrial activity. These findings indicate that Spyl expressing cells are undergoing 
cellular replication at a higher rate. Interestingly, Spyl overexpression has no affect on 
cellular proliferation when CDK2 kinase activity is inhibited. Depleting endogenous 
Spyl using small interfering RNA (siRNA) directed against Spyl, significantly decreases
11
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cell proliferation as well as CDK2 kinase activity. Moreover, RNAi knockdown of Spyl 
prevented cellular proliferation by inhibiting efficient S-phase entry (Porter et al. 2002). 
Thus, endogenous Spyl is an essential protein in normal cell growth.
Using full length Spyl as bait in a yeast two-hybrid screen identified p27 as a 
binding partner for Spyl. p27 is a CKI from Cip/Kip family which functions in the 
nucleus to inhibit the Cyclin E-CDK2 complex and prevent premature activation of this 
kinase and premature entry into S phase (Reynisdottir and Massague 1997; Slingerland 
and Pagano 2000; Nakayama et al. 2001). As mentioned above, one of the substrates of 
Cyclin E-CDK2 is p27. p27 is phosphorylated on Thr 187 as a result of activated CDK2. 
This phosphorylation at Thrl87 targets p27 for degradation via the SCFskp2 ubiquitin 
ligase pathway. Finally, decreasing p27 protein levels results in cell cycle progression 
through Gl/S transition. (Pagano et al. 1995; Morisaki et al. 1997; Sheaff et al. 1997; 
Vlach et al. 1997; Carrano et al. 1999; Montagnoli et al. 1999; Sutterluty et al. 1999; 
Tsvetkov et al. 1999). This dichotomy highlights the importance of studying alternative 
ways of activating CDK2; hence Spyl may represent a novel mechanism of relieving p27 
inhibition over CDK2 and will ultimately promote the degradation of p27. Along these 
lines, more detailed studies demonstrate that endogenous Spyl and endogenous p27 
interact in vivo. Spyl binds to the CDK-binding region of p27, but not the cyclin binding 
region of p27. Studies also demonstrate that Spyl, CDK2 and p27 can form a trimeric 
complex, in which increased levels of p27 cause increased association of Spyl with the 
complex and that CDK2 binding to Spyl is enhanced in the presence of p27. 
Mechanistically, Spyl overcomes a p27-induced Gl arrest by restoring CDK2 kinase 
activity via degradation of p27 (Porter et al. 2003). Furthermore, p27 null cells show the
12
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same proliferation rate as Spyl over expressing cells demonstrating that Spyl-induced 
proliferation depends on p27 degradation. This raises the possibility that Spyl enhances 
cell cycle progression by preventing the inhibitory actions of p27 on CDK2. Collectively 
these results demonstrate that Spyl plays a key role in regulating p27 inhibition of 
CDK2, and hence plays a primary role in promoting cell cycle progression through the 
Gl/S checkpoint (Porter et al. 2003).
Role of Spyl in the DNA Damage Response
In the fission yeast, Schizosaccharomyces pombe, radl is known to be one of the 
genes required for checkpoint control in the presence of DNA damage or in the absence 
of complete DNA replication (al-Khodairy and Carr 1992; al-Khodairy et al. 1994). As 
mentioned previously, X-Spyl rescues the radl-deficient fission yeast mutant strain from 
apoptosis following both ultraviolet irradiation (UV) and y-radiation treatments, 
suggesting that X-Spyl complements a radl deficiency in yeast (Lenormand et al. 1999). 
To investigate whether Spyl plays a role in the DNA damage response in mammalian 
cells a series of experiments were conducted. These results demonstrated that Spyl over 
expression increases cell survival after induction of DNA damage via different genotoxic 
agents such as camptothecin (CPT), cisplatin and hydroxyurea (HU) treatments. 
Furthermore it was demonstrated that survival effects were abolished when Spyl was 
knocked down via siRNA (Barnes et al. 2003). Clonogenic survival assays in the 
presence of CPT show that Spyl over expression increases cellular viability long term; 
suggesting that Spyl is not simply overcoming an essential DNA checkpoint (Barnes et 
al. 2003). Measuring fragmented DNA after CPT treatment of mammalian cells using an 
alkaline comet assay also shows that Spyl over expression decreases DNA fragmentation
13
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14
following damage. These results could indicate a decrease in damage to the DNA or it 
could indicate a decrease in the number of cells undergoing apoptosis (Barnes et al. 
2003). Interestingly, the survival effect of Spyl decreases upon expression of a CDK2 
dominant negative mutant indicating that, Spyl must both bind to and activate CDK2 in 
order to induce cell survival under genotoxic stress (Barnes et al. 2003). It has also been 
shown that endogenous levels of Spyl protein are upregulated after CPT, cisplatin and 
HU treatments of mammalian cells. Taken together, theses results clearly indicate that 
Spyl protein expression mirrors the expression of several checkpoint proteins, such as 
E2F, p53 and p21, which are upregulated after genotoxic stresses (Kastan et al. 1991; 
Blattner et al. 1999).
While the above-mentioned experiments reveal a role for Spyl in protecting the 
cell from death following DNA damage they tell us little about the mechanism by which 
this is occurring. To investigate this mechanism further investigators have studied the 
role of Spyl following UV radiation. Various flow cytometry experiments show that 
Spyl expression inhibits apoptosis in response to UV radiation. These effects were 
shown to occur because Spyl inhibits activation of pro-apoptotic pathways (Gastwirt et 
al. 2006). Also, Spyl expression allows for UV irradiation resistant DNA synthesis and 
permits cell progression to mitosis in the presence of DNA damage. These results 
indicate that Spyl inactivates both Gl/S and G2/M checkpoints in response to DNA 
damage (Gastwirt et al. 2006). Further studies demonstrate that Spyl inhibits activation 
of checkpoint proteins such as Chkl, RPA32 and the histone variant H2A.X in response 
to UV irradiation. Mutations within the Speedy/RINGO box of Spyl, known to mediate 
the interaction with and activation of CDK2 (Cheng et al. 2005b; Dinarina et al. 2005),
14
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prevent inactivation of Chkl and RPA32 in response to UV induced DNA damage. Thus, 
Spyl-CDK2 interaction is essential for Spyl-mediated DNA damage effects, but not 
Spyl-induced proliferation (Gastwirt et al. 2006). Collectively these experiments suggest 
that Spyl is functioning to inhibit specific apoptotic events following DNA damage; an 
activity that may be harmful for long-term growth effects of the cell.
Speedy/RINGO Protein Family
Investigations into Spyl homologues have suggested that these proteins are 
members of a novel protein family (Cheng et al. 2005b; Dinarina et al. 2005). Speedy like 
genes have been identified in the most primitive branching clade of chordates (Ciona 
intestinalis), demonstrating that they are well conserved among vertebrates (Cheng et al. 
2005b). Recently, speedy like genes have been placed in a large family of vertebrate 
proteins designated the Speedy/RINGO family. Speedy/RINGO family of vertebrate cell 
cycle regulators, control cell proliferation and cell survival through the atypical activation 
of CDKs.
In mammals there are at least five functional isoforms of Speedy; two SpeedyA 
(SpeedyAl and SpeedyA2), SpeedyB, SpeedyC, and SpeedyD. It has been suggested that 
the two isoforms of SpeedyA are the result of spliced variants. SpeedyAl and SpeedyA2 
have been identified in both Homo sapiens (chromosome 2) and Mus musculus 
(chromosome 17). SpeedyAl is widely expressed in many tissues and cell lines. SpeedyB 
has been identified in Mus musculus (chromosome 5) and it is testis specific. SpeedyC 
has been identified in Homo sapiens (chromosome 11) and is expressed specially in 
tissues that undergo polyploidy. SpeedyD has also been identified in Mus musculus 
(Cheng et al. 2005b). Although Speedy expression patterns differ throughout the body,
15
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testis is considered a Speedy enriched tissue, as it expresses all known forms of Speedy in 
high levels. This is consistent with the X-Spyl functions during meiosis (Cheng et al. 
2005b).To simplify the nomenclature Spyl will be used throughout this thesis to 
represent human SpeedyAl; any other isoform of Spyl will be written out in full and any 
other species will be represented by a hyphenated letter in front of the protein/gene.
The members of the Speedy/RINGO family share high sequence homology 
within a central region known as the Speedy/RINGO box (S/R Box). Speedy/RINGO box 
is a conserved region of around 100 amino acids which is essential for CDK2 binding and 
activation (Cheng et al. 2005b; Dinarina et al. 2005). Spyl and its homologs activate 
CDK2 in the absence of known mechanism of activation (Cheng et al. 2005b). Both 
mammalian SpeedyA and C bind to CDK1 and CDK2. Mammalian SpeedyB binds 
preferably to CDK1. Interestingly, both SpeedyA and B promote Xenopus oocyte 
maturation, even though they bind preferentially to different CDKs (Cheng et al. 2005b). 
Mutations in the Speedy/RINGO box abrogate both CDK binding and oocyte maturation 
(Dinarina et al. 2005). In addition to the central Speedy/RINGO box, the C-terminal 
region of SpeedyA promotes CDK activation, whereas the N-terminal region influences 
Spyl protein expression (Cheng et al. 2005b).
Moreover, it has been shown that CDK2 complexed with the SpeedyA2 isoform 
displays broader substrate specificity in comparison to CyclinA-CDK2. CDK2-SpeedyA2 
prefer noncanonical CDK2 substrates such as a KSPRY peptide or the CDC25 
phosphatases which contain non-canonical CDK phosphorylation sites (Cheng et al. 
2005a)
16
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
17
The Mammary Gland as a Model System for Development and Cancer
Our research group and others’ have determined that Spyl protein levels are 
elevated in many aggressive forms of cancer, including invasive ductal carcinoma of the 
breast (Zucchi et al. 2004). For this reason we have focused on characterizing the 
molecular pathways regulating Spyl protein levels in the proliferating mammary gland. 
Proliferation of the mammary gland is a normal step in development; occurring 
periodically both during embryogenesis as well as throughout the life of the organism. 
One of the principal objectives of my research is to understand the role of Spyl in normal 
mammary gland development, and to determine potential alterations that happen in breast 
cancer. In addition, the developing mammary gland is an ideal model system for studying 
genes involved in cell cycle regulation because it is one of the few organs that undergoes 
cycles of proliferation, differentiation and apoptosis throughout the life of the organism 
and it is not essential for the viability of the animal, making manipulation of the gland 
feasible.
Mouse mammary gland development begins at embryonic day 11 by formation of 
5 mammary placodes along the two milk lines. These placodes form the epithelial buds 
within one day. At embryonic day 15.5, each epithelial bud elongates by invasion into the 
mammary fat pad and forms a sprout. Each sprout forms a lumen that opens to the skin 
surface and the nipple forms. At embryonic day 16 the first branching of the sprout 
occurs, and by embryonic day 18.5 the sprouts have developed into small tree like glands 
(Veltmaat et al. 2003). After birth, the mammary gland grows isometrically with body 
growth. At puberty, different hormones induce differentiation and the mammary gland 
starts to grow allometrically. Pubertal mammary gland development is driven by the
17
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changes occurring in the terminal end buds (TEBs). TEBs are highly proliferative 
structures which drive ductal elongation and invade into the mammary fat pad (Ball 
1998).
At a molecular level, embryonic development of the mammary gland is dependent 
on epithelial-mesenchymal signaling (Hennighausen and Robinson 2001). In vivo studies 
show that after the embryonic and prepubertal stages of mammary gland, further 
development of the gland becomes hormone dependent. At the onset of puberty 
epidermal growth factor (EGF) signals through the mammary gland stroma and controls 
early ductal outgrowth. Different hormone depletion studies have revealed specific 
steroid hormones that regulate mammary gland development. In addition to EGF, 
hormones such as estrogen stimulate rapid proliferation, and, together with progesterone, 
promote extensive lateral branching of mammary gland epithelia (Medina 1996). It is 
well known that estrogen acts directly on the mammary gland and stimulates ductal 
elongation and branching during puberty (Silberstein et al. 1994). Further studies link 
estrogen action with the cell cycle machinery demonstrating a role for estrogen in the 
Gl/S transition (Osborne et al. 1984; Leung and Potter 1987a; Leung and Potter 1987b; 
Altucci et al. 1996; Foster and Wimalasena 1996; Planas-Silva and Weinberg 1997; Prall 
et al. 1998). In this stage of development, estrogen binds to estrogen receptors (ERs), 
which are members of nuclear receptor super family of transcription factors. The 
estrogen-ER complex then regulates transcription of target genes via binding to DNA 
enhancer elements located in the promoter regions directly or in association with other 
coregulators (Bocchinfuso and Korach 1997b; Bocchinfuso and Korach 1997a; Weihua et 
al. 2003). It is also known that estrogen has a rapid and direct effect on regulation of the
18
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transcription factor c-Myc (Dubik et al. 1987). Strong evidence places c-Myc among the 
key players in mediating estrogen action (Watson et al. 1991; Prall et al. 1998). This 
information makes estrogen a potential candidate in the upstream regulation of Spyl 
during mammary gland development.
Early in pregnancy, epithelial cells in the quiescent mammary gland respond to 
release hormones such as prolactin and placental hormones, and begin to rapidly 
proliferate (Traurig 1967). Prolactin is a pituitary peptide hormone that regulates growth 
and differentiation of epithelial cells and sustains milk production. Prolactin binds to the 
prolactin receptor; resulting in the dimerization and activation of the receptor. This event 
in turn stimulates the activation of a receptor associated tyrosine kinase named Janus 
Kinase (JAK2) (Darnell et al. 1994; Schindler and Darnell 1995). JAK2 phosphorylates 
two members of the transcription factor family of signal transducers and activators of 
transcription (STAT), STAT5A and STAT5B (Ihle 1996). Activated STATs go to the 
nucleus and promote expression of target genes by direct binding to DNA via y-interferon 
activated sequence. Two y-interferon activated sequences are located in the promoter of 
the milk protein P-casein, and this protein is upregulated by STAT5 (Schmitt-Ney et al. 
1991; Burdon et al. 1994). At birth, epithelial differentiation occurs to allow lactation 
(Robinson et al. 1995). After weaning, there is a rapid involution of the gland through the 
induction of apoptosis (Walker et al. 1989). Studies show that there are other regulatory 
signaling pathways including growth factors, proto-oncogenes and tumor suppressors 
also involved in mammary gland development at the cellular level (Rosen et al. 1994;
Han et al. 1995; Streuli et al. 1995; Han et al. 1996; Sgambato et al. 1996; Grolli et al. 
1997; Baratta et al. 2000; Baratta et al. 2003; Katayama et al. 2003). Among these
19
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factors, the EGF family of ligands has a significant role in promoting proliferation and/or 
differentiation through several signaling pathways. EGF ligands are expressed throughout 
the development of the mammary gland (Schroeder and Lee 1998; Sebastian et al. 1998). 
These hormones bind to transmembrane tyrosine kinase ErbB receptors. Ligand binding 
stimulates receptor dimerization, then activation of tyrosine binding domain. Tyrosine 
phosphorylation of the receptor recruits proteins containing a Src homology 2 (SH2) 
domain to the receptor. This event causes activation of several proteins via 
phosphorylation, including those involved in the MAPK signaling pathway (Boonstra et 
al. 1995). EGF receptor also phosphorylates the ER, which in turn leads to ligand 
independent activation of ER to mediate estrogen induction of end bud formation in the 
developing gland (Kato et al. 1995; Bunone et al. 1996; Ankrapp et al. 1998; Tremblay et 
al. 1999). Importantly, improper regulation of these signaling pathways can lead to 
mammary epithelial hyperplasia and ultimately to mammary gland tumorigenesis 
(Engelman et al. 1998).
Cellular Models of Mammary Gland Morphogenesis
At a cellular level mammary epithelial cells have highly definitive morphological 
features that are essential for proper cellular function; they have a polarized morphology, 
specialized cell-cell contacts and are attached to an underlying basement membrane. 
These characteristics contribute toward the function and development of the mammary 
gland and disruption of the epithelial cell architecture is a precipitating factor in the 
pathogenesis of epithelial tumors (Fauquette et al. 1997).
The HC11 cell line has been employed as a model system to study growth and 
differentiation of mammary epithelial cells (Marte et al. 1995; Baratta et al. 2000). These
20
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cells, originally isolated from normal mid-pregnant BALB/c mice, retain the ability to 
differentiate in response to lactation hormones (dexamethasone and prolactin) (Doppler et 
al. 1989). Importantly, the HC11 cell line is one of the few non-transformed, clonal 
mammary epithelial cell lines that can be utilized in studies of mammary cell 
morphogenesis. During differentiation these cells secrete laminin, interact appropriately 
with the extracellular matrix and form spherical structures which mimic the 
mammospheres formed by primary mouse mammary epithelial cells and acini in the 
intact gland (Humphreys and Rosen 1997).
This project focuses around the hypothesis that the novel cell cycle protein Spyl 
plays a key role in mammary gland development and breast tumorigenesis. Herein we 
describe the regulation of Spyl at protein and mRNA level throughout development of 
the mammary gland and we begin to unravel the signaling mechanisms regulating Spyl 
expression. Importantly we determine the effects of altering Spyl expression levels on 
mammary gland development and we demonstrate a putative role for Spyl in the 
development of breast cancer.
21




HC11, BALB/c mouse mammary epithelial cell line (provided by Dr. C. 
Shermanko; University of Calgary) and MCF7, human mammary adenocarcinoma 
epithelial cell line (provided by Dr. Andrew V. Hubberstey; University of Windsor) were 
maintained in RPMI 1640 medium (Hyclone) containing 10% (vol/vol) fetal calf serum 
(Sigma). HC11 cells medium was supplemented with 5 pg/ml insulin (Sigma), and 10 
ng/ml EGF (Calbiochem). Myc ER™ MEF, mouse embryonic fibroblast cells (provided 
by Dr. G.I. Evan; UCSF) and Phoenix cells (purchased from ATCC) were maintained in 
DMEM medium (Sigma) containing 10% (vol/vol) fetal bovine serum (Sigma). Myc 
ER™ MEF cells medium was supplemented with 5pg/ml puromycin. HTB125, human 
mammary normal cell line and HTB126, human mammary carcinoma cell line (provided 
by Dr. S. Pandey; University of Windsor) were maintained in Modified Dulbecco's 
medium (Sigma) containing 10% (vol/vol) fetal bovine serum (Sigma). HTB 125 medium 
was supplemented with 30 ng/ml EGF (Calbiochem) and HTB 126 medium was 
supplemented with 0.01 mg/ml bovine insulin (Sigma). All the cell lines were maintained 
in medium containing 2mM L-glutamine (Sigma), penicillin (Invitrogen), and 
streptomycin (Invitrogen) and were maintained in a 5% C02 environment.
Plasmids and Constructs
The (3-casein-luciferase construct (provided by Dr. M. David; UCSD) contains 
residues -344 to -1 of the P-casein promoter in front of a promoterless luciferase gene. 
The promoterless luciferase vector, pSVOAL delta 5’Luc, was constructed using
22
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pLucDSS vector. This fragment of p-casein promoter is cloned between Hind III/BamHI 
restriction sites of pSVOAL delta 5’Luc (Gouilleux et al. 1991; Gouilleux et al. 1994). 
The flag-Spyl-pLXSN construct was previously described (Porter et al. 2003). The Myc- 
ER™ construct (provided by Dr. G. Evan; UCSF) was generated by fusing the 5’ end of 
DNA encoding amino acids 281-599 of G525R mutant estrogen receptor to the 3’ end of 
DNA encoding amino acids 1-435 of c-Myc to form Myc-ER™. This DNA fragment was 
cloned into pBabe-puro (Eilers et al. 1989; Morgenstem and Land 1990a; Morgenstem 
and Land 1990b; Danielian et al. 1993; Littlewood et al. 1995)
Stable Cell Lines and Transfections
Flag-Spy 1 -pLXSN-HC 11 (Spyl-HCl 1) and pLXSN-HCl 1 (Cntl-HCl 1) stable 
cell lines were generated using Phoenix Amphotropic System as previously described 
(Kinsella and Nolan 1996; Grignani et al. 1998; Yang et al. 1999). Subconfluent phoenix 
cells were treated with 25 pM chloroquine (Sigma) 5 min prior to transfection and then 
transfected separately with flag-Spyl-pLXSN and pLXSN using the BBS/calcium 
phosphate precipitation method (Chen and Okayama 1987). Infectious flag-Spyl-pLXSN 
and pLXSN viruses were collected 48 hr post transfection. HC11 cells were incubated 
with retrovirus for 24 hr in the presence of 5 pg/ml polybrene (Sigma). HC11 growth 
media was supplemented with the selection antibiotic, 400 pg/ml G418 (Sigma), 48 hr 
post infection. G418 resistant clones were selected and maintained in HC11 cell growth 
media supplemented with 400 pg/ml G418. Cell lysate of representative clones were 
analyzed on 10% polyacrylamide-SDS gels and transferred to PVDF-PLUS transfer 
membrane. Expression of flag-Spyl was determined by immunoblotting with both flag 
specific monoclonal antibody (Sigma) and Spyl polyclonal antibody.
23
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Lactogenic Hormone Induced Differentiation
HC11 cells were grown to confluence and maintained for two to three days in 
growth media to confer competent cells capable of responding to lactogenic hormones.
To induce differentiation; EGF-containing media was removed, the cells were rinsed 
twice with PBS, and then incubated in differentiation media containing R PM I1640 
medium, 1% fetal calf serum, 2mM L-glutamine, 5 pg/ml insulin, lpM  dexamethasone 
(Sigma), 5 pg/ml prolactin (Sigma), penicillin and streptomycin for three days. To assess 
differentiation P-casein luciferase was transfected into HC11 cells during the growth 
phase using ESCORT™ II Transfection Reagent as suggested by the manufacturer 
(Sigma). Luciferase activity was monitored using the Luciferase Assay System 
(Promega) and Wallac Victor Reader3 (Perkin Elmer).
Immunoblotting
Total protein was isolated from cell cultures by harvesting cells and lysing in 
0.1% NP-40 lysis buffer (5 ml 10% NP-40, 10 ml 1M Tris pH 7.5, 5 ml 0.5M EDTA, 10 
ml 5M NaCl up to 500 ml RO water) containing protease inhibitors (10 pl/ml PMSF 
stock solution 10 mg/ml, 3 pl/ml aprotinin stock solution 20 mg/ml, 10 pl/ml leupeptin 
stock solution 1 mg/ml) for 30 minutes on ice. Total protein was extracted from frozen 
mammary gland tissue as previously reported for whole cell extract preparation from 
mammary gland (Zahnow et al. 1997). For all protein isolations; Bradford Reagent was 
used to determine the concentration of proteins in lysates following the manufacturer’s 
instruction (Sigma). Aliquots of lysates containing 20-30 pg protein were subjected to 
electrophoresis on denaturing SDS-10% polyacrylamide gels and transferred to PVDF- 
Plus 0.45 micron transfer membranes (Osmonics Inc.) for 3 hr at 30V using a wet transfer
24
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method. Blots were blocked for 2 hrs in TBST containing 3% non-fat dry milk (blocker) 
at room temperature, primary antibodies were reconstituted in blocker and incubated over 
night at 4 degrees, secondary antibodies were used at a 1:10,000 dilution in blocker for 1 
hr at room temperature. Blots were washed three times with TBST following incubation 
with both the primary and secondary antibodies. Washes were 20 min. each following the 
primary antibody and 10 min. each following the secondary antibody. 
Chemilumiminescent Peroxidase Substrate-3 was used for visualization following the 
manufacturer’s instruction (Sigma). Chemiluminescence was quantified on an Alpha 
Innotech HD2 (Fisher) using AlphaEase FC software.
RT-PCR Reactions
Total RNA was extracted using RNeasy Plus (Qiagen). RNA quality and quantity 
were analyzed using RNA 6000 Nano Assay and 2100 Bioanalyzer (Agilent). DNase 
treatment of each RNA sample was performed prior to RT-PCR using RQ1 RNase-Free 
DNase Kit (Promega). For endpoint RT-PCR reverse transcription was carried out using 
Superscript ™ II Reverse Transcriptase (Invitrogen). Taq PCR (New England Biolab) 
was used for the PCR reaction using following primers, all designed to span the exon- 
exon junction:
mMyc- forward primer (A010) AGCCCCTAGTGCTGCATGAG, reverse primer (A011) 
GTTTGCCT CTT CTCC AC AG AC A
mP-casein- forward primer (A012) CCGTTTCTGTCTAAGAGGATTTCC, reverse 
primer (A013) GCATGATCCAAAGGTGAAAAGAT
mGAPDH- forward primer (A006) TGAAGCAGGCATCTGAGGG, reverse primer 
(A007) CG AAGGT GG A AG AGT GGGAG
25
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26
Spyl- forward primer (A091) CCATGGGCTTTAGGGAAAAAC, reverse primer 
(A073) TGGCCATAACCTCCTCACAAC
Spyl - forward primer (A092) TCTAAACGCCCCAAAGGACC, reverse primer (A093) 
GTC AT AGCC AAAAG AT ACTT GT CT GC
hGAPDH- forward primer (A087) GCACCGTCAAGGCTGAGAAC, reverse primer 
(A088) GGATCTCGCTCCTGGAAGATG. PCR cycles were optimized to ensure that 
end-point measures were on a log-phase scale, in all blots shown 25 amplification cycles 
were used. All PCR products were separated on 8% polyacrylamide gel electrophoresis, 
visualized on Chemi Genius Bio Imaging System (Syngene) after ethidium bromide 
staining using GeneSnap (Syngene) and quantified using Gene Tools (Syngene) software
Mammary Gland Development Assays
Mammary gland tissues were collected from C57BL/6 female mice during 
developmental time course. C57BL/6 mice were maintained following the guidelines of 
the Association for Assessment of Laboratory Animal Care and the assay carried out as 
outlined in University of Tennessee Health Science Center, protocol #1422. Tissues were 
either paraffin embedded for immunocytochemistry or flash frozen for use in western 
blots or mRNA analysis. Fat pad transplant assays were conducted using BALB/c mice, 
which are syngeneic for the HC11 cell line. BALB/c mice were maintained following the 
guidelines of the Canadian Council on Animal Care and the assay carried out as outlined 
in University of Windsor AUPP #06-19. Stable Spyl-HCl 1 cells and Cntl-HCl 1 cells 
(5><105 cells) were injected into the cleared fat pad of 4th pair mammary glands of 22 day 
old mice and allowed to grow for 8-16 weeks. Tumor incidence was monitored weekly 
after 4 weeks by palpitation of the gland. Whole mount carmine alum staining of
26
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mammary gland was performed as previously described (Fata et al. 2001). Mammary 
gland whole mounts were visualized on a Leica MZFLIII dissecting scope, pictures taken 
using Northern Eclipse software. BALB/c mice utilized for lactation studies were bred at 
8 weeks post-transplantation and were sacrificed on days 1 or 2 following birth of the 
pups. Mammary glands were embedded for sections, flash frozen for RT-PCR analysis or 
prepared for whole mount.
Histological Analysis
Mammary glands were harvested, immediately fixed in 4% paraformaldehyde 
over night and stained with hematoxylin/eosin as previously described ((Lenferink et al. 
2000). Briefly, paraffin-embedded mammary glands were sectioned (6 pm) and stained 
with Mayer’s hematoxylin and eosin B-phyloxine (Sigma). IHC was done on mouse 
mammary gland tissues over the development time course using Spyl antibody (1:250) 
and using IgG staining as a negative control.
Estrogen and Tamoxifen Treatments
Fetal calf serum was treated with charcoal, dextran coated (Sigma) over night at 
4C. MCF7 cells were maintained in the medium supplemented with charcoal treated 
serum for 5 days prior to estrogen treatment. These cells then were treated with 10 nM 
17-P-estradiol (Calbiochem) as well as the vehicle control (DMSO) over the experimental 
time course. For tamoxifen treatment, MCF7 cells were treated with 10 nM 4-hydroxy- 
tamoxifen (Sigma) and the vehicle control (DMSO) over the same time course in the 
presents of estroid hormones. Cell lysate of representative samples were analyzed on 
10% polyacrylamide-SDS gels and transferred to PVDF-PLUS transfer membrane.
27
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Expression of endogenous Spyl was determined by immunoblotting with Spyl 
polyclonal antibody.
28
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CHAPTER IV
ANALYSIS OF RESULTS
Spyl protein and mRNA levels are tightly regulated during mammary gland 
development.
Utilizing a mouse model of mammary gland development, tissue was collected at 
various time points during development and prepared for protein and mRNA analysis. 
Immunostaining demonstrates that Spyl is primarily localized to the epithelial cells, and 
that expression is absent or weak in the myoepithelial cells as well as in adipose tissue 
(Figure 1 A). Immunostaining of tissues during lactation demonstrate that there is only an 
occasional, weakly positive epithelial cell; however low-level expression of Spyl in 
adipose cells appears to be maintained. Expression patterns seen by immunostaining are 
mimicked by western blot analysis where Spyl protein levels are elevated in early 
pregnancy and are dramatically reduced at peak lactation, coinciding with cell 
differentiation (Figures IB). Interestingly, at 4 days post-weaning, a period of peak 
involution, Spyl expression is upregulated again. These data implicate Spyl in the 
proliferative and apoptotic stages of mammary gland development. Figure 1C 
demonstrates that this expression is regulated at an mRNA level. Spyl mRNA is elevated 
during early pregnancy and is depleted at 15 days pregnancy, a time when the gland 
begins to undergo terminal differentiation, as indicated by P-casein expression.
29
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Figure 1
Spyl protein is tightly regulated in the developing mouse mammary gland. 
C57BL/6 female mice were studied over a developmental time-course including mature 4 
week virgin mice (Virgin), 6,10, 15, 17.5 days into pregnancy (6 Preg; 10 Preg; 15 Preg; 
17.5 Preg), 10 day post-lactation (lactation) and 4 days involution (involution). (A) 
Mammary glands were isolated, paraffin embedded and prepared for 
immunohistochemistry. Staining was carried out using Spyl antibody or secondary 
antibody only as the control (IgG control). (B) Mammary glands were homogenized and 
protein extracts were analyzed by 10% SDS-PAGE followed by immunoblotting with 
Spyl antibody. Equal protein was loaded in each lane as determined by Bradford protein 
assay and confirmed by immunoblotting the same blot with actin antibody. (C)
Mammary glands were homogenized and total RNA extracts were analyzed by RT-PCR 
using random hexamer primers for first strand c-DNA generation followed by PCR using 
Spyl specific PCR primers. Equal RNA was used as determined by RNA nano assay and 
confirmed by equal GAPDH levels in all reactions and P-casein mRNA levels were 
utilized as a marker for differentiation.
30
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Spyl upregulation in the proliferating mammary gland occurs via a MAPK- and c-Mvc- 
dependent signaling mechanism.
Using the HC11 cell system we have determined that Spyl protein (Figure 2A) 
and mRNA levels (Figure 2B) are high in proliferating HC11 cells and are drastically 
depleted at 3 days post-differentiation, a time period that is coincident with the onset of 
P-casein protein expression, as indicated with both P-casein mRNA expression (Figure 
2B, lower panel), and luciferase reporter activity (Figure 2C). Cells grown to confluence, 
to infer the competency of the cells to respond to differentiation stimuli, do not show any 
significant reduction in Spyl expression over loading controls. To investigate the 
possible signaling pathways mediating this controlled expression of Spyl we treated 
proliferating HC11 cells with a variety of different hormones or inhibitors and studied the 
direct effects on Spyl protein expression. Figure 2D demonstrates that treatment with 
inducers of differentiation, prolactin and dexamethasone, do not directly down regulate 
Spyl protein levels as compared to vehicle (DMSO) alone treatment (upper panel; lanes 
1-3). However, treatment with the MAPK inhibitor PD98058 significantly reduced Spyl 
protein levels (upper panel; lane 5), suggesting that Spyl expression is dependent on 
active MAPK signaling. Levels of Spyl were not altered by SB202474 which is the 
negative control for MAPK inhibition studies (upper panel; lane 4).
32
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Figure 2
Spyl protein is tightly regulated in different developmental stages o f  the HC11 
cell line. HC11 cells were cultured to confluence and differentiation was induced by 
incubation of competence cells for three days in differentiation media. Cells were 
analyzed during proliferation (Pro), confluence (Con), day three and day five post­
differentiation (D3, D5). (A) Total protein was extracted and analyzed by 10% SDS- 
PAGE followed by immunoblotting with Spyl antibody. Equal protein was loaded in 
each lane as determined by Bradford protein assay and confirmed by immunoblotting the 
same blot with actin antibody. (B) Total mRNA extracts were analyzed by RT-PCR using 
random hexamer primers to generate first strand c-DNA followed by PCR using Spyl 
specific PCR primers. Equal RNA was used in each RT-PCR reaction as determined by 
RNA nano assay and confirmed by equal GAPDH levels in all reactions. P-casein mRNA 
levels were utilized as a marker for differentiation. (C) HC11 cells were transfected in 
parallel to experiments described above (A & B). Cells were seeded in triplicate and were 
transfected with a vector expressing luciferase behind the P-casein promoter. Luciferase 
activity is reported for 3 separate samples from days 1-4 during proliferation (P1-P4), as 
well as during confluence (C) and days 3 and 5 post-differentiation (D3, D5). Error bars 
reflect the standard error of the mean between triplicate samples. (D) Proliferating HC11 
cells were treated with Dexamethasone (DEX), Prolactin, vehicle control (DMSO), lpM 
inhibitor control (SB202474) and lpM  MAPK inhibitor (PD98058). Total protein was 
extracted and analyzed by 10% SDS-PAGE followed by immunoblotting with Spyl 
antibody. Equal protein was loaded in each lane as determined by Bradford protein assay 
and confirmed by immunoblotting the same blot with actin antibody.
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Expression of c-Myc is involved in processes of growth, neoplasia and apoptosis 
(Marcu et al. 1992; Ryan and Bimie 1996). c-Myc expression is tightly regulated in the 
mammary gland and reflects a similar pattern of expression as that observed with Spyl; 
being downregulated during differentiation, and upregulated during states of proliferation 
or during apotosis (Ryan and Bimie 1996; Grolli et al. 1997). Due to these similarities, 
and the known involvement of the MAPK signaling pathway upstream of Spyl, we 
wished to determine whether Spyl could be a downstream target for c-Myc signaling. To 
do this we utilized a Myc-ER™ inducible cell system (Littlewood et al. 1995). Different 
estrogen dependent proteins have been fused with the hormone binding domain (HBD) of 
estrogen receptor (ER) to create an inducible protein expression system. There are 
advantages and disadvantages with ER-HBD fusion proteins. Estrogen is available, 
inexpensive and many cell types lack endogenous ER. However, disadvantages persist 
with regard to the presence of estrogen in the preferred media and serum and the 
inefficiencies which may be related to depletion, using charcoal-dextran treatment. 
Additionally, there have been issues with regard to the amount of transcriptional activity 
of the ER-HBD fusion proteins occurring as a result of the hormone binding domain of 
ER (Webster et al. 1988; Lees et al. 1989; Tora et al. 1989; Berry et al. 1990; Danielian et 
al. 1993; Schuermann et al. 1993). The Myc-ER™ system utilizes a mutant murine ER 
(ER™) that no longer binds to estrogen , so it does not exhibit any transactivation 
activity, but it binds to tamoxifen (Danielian et al. 1993; Littlewood et al. 1995). 
Tamoxifen treatment releases the inhibitory effect of receptor, thereby activating the 
fusion protein; c-Myc (Littlewood et al. 1995). The Myc-ER™ mouse embryonic 
fibroblast (MEF) cell line stably expresses c-MycER™ chimeric protein; and c-Myc
35
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activities that are dependent on tamoxifen (Littlewood et al. 1995). Since MEFs do not 
express endogenous ER, all the effects of hormone can be attributed to the action of c- 
Myc.
Using MEF cells lacking the Myc-ER™ fusion (Myc-ER™-; left panels) as a 
control or the Myc-ER™ MEF cell line (Myc-ER™+; right panels), we addressed 
whether c-Myc has a direct effect on Spyl expression. Figure 3A demonstrates that the 
Myc-ER™+ cells turn on c-Myc protein after 15 min. of tamoxifen treatment (upper 
panels). This figure further demonstrates that Spyl protein levels are elevated 
significantly by 30 min. following the induction of c-Myc (middle panels). Next we 
wanted to determine whether this induction was occurring at the mRNA level. As seen in 
Figure 3B, Spyl mRNA levels accumulate significantly at 1 hr. post-treatment with 
tamoxifen. In order to determine whether Spyl induction by c-Myc requires de novo 
protein synthesis, mRNA levels of Spyl were monitored through a time course of 
tamoxifen treatment in the presence of the protein synthesis inhibitor cyclohexamide. 
Even in the absence of de novo protein synthesis Spyl mRNA levels were elevated 
following treatment with tamoxifen (Figure 3C; upper panel lanes 1-5). This 
accumulation was not a result of the cyclohexamide treatment alone (lanes 6-8). These 
results were quantified as described in materials and methods, and data was expressed as 
bar graph (Figure 3D). These experiments demonstrate that c-Myc, an established 
regulator of mammary gland proliferation, is capable of activating Spyl mRNA and 
protein expression. Whether c-Myc is functioning directly as a transcription factor for 
Spyl remains to be determined. This exciting correlation between Spyl and the oncogene
36
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c-Myc emphasizes the importance of understanding how Spyl is regulated during 
mammary gland development since it may provide future relevance to the understanding 
of breast cancer.
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Figure 3
Spyl protein levels are regulated downstream o f c-Myc. (A) Myc-ER™- MEF 
control cells (left hand panels) and Myc-ER™+ MEF cells (right hand panels) were 
treated with lOOnM tamoxifen (TAM) and total protein extracts collected at different 
time points (Omin, 15min, 30min, 45min, 60min, 90min and 240min). Lysates were 
analyzed by 10% SDS-PAGE followed by immunoblotting with c-Myc antibody (upper 
panel), Spyl antibody (middle panel). Equal protein was loaded in each lane as 
determined by Bradford protein assay and confirmed by immunoblotting the same blot 
with Actin antibody (lower panel). (B) Myc-ER™+ MEF cells were cultured and treated 
with lOOnM TAM and total mRNA collected at various time points (Ohr, lhr and 4hr). 
RT-PCR was performed using random hexamer primers to generate first strand cDNA 
followed by PCR using Spyl and GAPDH specific PCR primers. Equal RNA was used in 
each RT-PCR reaction as determined by RNA nano assay and confirmed by equal 
GAPDH levels in all reactions. (C) Myc-ER™+ MEF cells were cultured and treated 
with 50 pg/ml cyclohexamide (CHX) 30 min. prior to TAM treatment as described in 
materials and methods. Total mRNA extracts at various time points (Ohr, lhr, 2hr, 3 hr 
and 4hr) were analyzed by RT-PCR using random hexamer primers to generate first 
strand c-DNA followed by PCR using Spyl specific PCR primers. Equal RNA was used 
in each RT-PCR reaction as determined by RNA nano assay and confirmed by equal 
GAPDH levels in all reactions. Spyl mRNA is present after activation of c-Myc protein 
via TAM treatment (lhr, 2hr, 3hr and 4hr) (lanes 2-5). Spyl mRNA is not detectable 
before activation of c-Myc protein (0 hr; lane 1). Cyclohexamide (CHX) treatment alone 
has no significant effect on Spyl mRNA levels (lanes 6-8). (D) Levels were quantified
38
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using Synsnap analysis program of Syngene (Perkin Elmer). X-axis indicates lanes from 
Figure 3C and y-axis demonstrates relative Spyl expression.
39
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The downregulation of Spyl is essential for terminal differentiation
Three different plates of HC11 cells were infected using different batches of 
retrovirus as described in materials and methods. 24 individual stable HC11 colonies 
were tested for their flag expression ability (Figure 4A). Using stable HC11 cell lines 
which over express either flag-tagged Spyl (Spyl-HCl 1) or an empty vector control 
(Cntl-HCl 1) (Figure 4B), we sought to determine the effects of preventing Spyl down 
regulation on mammary cell differentiation. Here both the control and Spyl expressing 
cells were subject to a normal differentiation time course and mRNA was collected from 
cells throughout the phases of growth, confluency and differentiation. The control cell 
line shows a reduction of Spyl mRNA co-incident with the onset of P-casein expression 
at day 2 post-differentiation (D2) and a depletion of detectable mRNA by day 3 post- 
differentiation (D3) (Figure 4C). In contrast to this, when Spyl levels are maintained via 
a foreign promoter, p-casein expression is barely detectable throughout the remainder of 
the differentiation time course (Figure 4D). These results were quantified as described in 
materials and methods, and data was expressed as a bar graph (Figure 4E). These results 
strongly suggest that the down regulation of Spyl is required for differentiation to occur.
42
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Figure 4
Abundance o f the Spyl transcript suppresses terminal differentiation. (A) Three 
different plates of HC11 cells were infected using different batches of retrovirus. 24 
individual stable HC11 colonies were tested for their flag expression ability. Protein 
expression was analyzed by 10% SDS-PAGE followed by immunoblotting with flag 
antibody (upper panel). Equal protein loading was determined by Bradford protein assay 
and confirmed by immunoblotting the same blot with actin (lower panel). (B) Stable flag- 
tagged Spyl over expressing HC11 cells (Spyl-HCl 1) were generated using retroviral 
gene transfer technology, an empty flag-empty vector (PLXSN) was also virally infected 
to use as a control cell line (Cntl-HCl 1). Following several passages under antibiotic 
selection total protein extracts were collected from Spyl-HCl 1 and Cntl-HCl 1 cells. 
Protein expression was analyzed by 10% SDS-PAGE followed by immunoblotting with 
flag antibody (upper panel) and endogenous Spyl antibody (middle panel). Equal protein 
loading was determined by Bradford protein assay and confirmed by immunoblotting the 
same blot with actin. (C & D) Total mRNA was collected from Spyl-HCl 1 (D) or Cntl- 
HCl 1 (C) cells during proliferation (Pro), confluency (Con), and post-differentiation over 
a period of 6 days (D2-D6). Samples were analyzed by RT-PCR using random hexamer 
primers to generate first strand cDNA followed by PCR using Spyl (upper panel), (3- 
casein (middle panel) and GAPDH (lower panel) specific primers. Equal RNA was used 
in each RT-PCR reaction as determined by RNA nano assay and confirmed by equal 
GAPDH levels in all reactions (lower panel). (E) Bands from RT-PCR analysis in parts 
C&D above were quantified using the Synsnap analysis program following visualization 
on the Syngene Gel Documentation system (Perkin Elmer). P-casein levels were
43
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normalized with corresponding GAPDH levels and are graphically depicted. The X-; 
reflects development time course 4 C & D and the Y-axis indicates relative P-casein 
expression.
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Interestingly, when cultured to promote acini formation, the Spyl-HCl 1 cells, 
unlike the Cntl-HCl 1 counterparts, are not capable of forming acini-like spheroids during 
development (Figure 5). Even during confluency Spyl-HCl 1 cells have a propensity to 
generate disorganized piles of cells rather than remaining as an organized blanket of cells 
such as the Cntl-HCl 1 line (Figure 5; top panel). These data demonstrate that, at a 
cellular level, Spyl over expression alters the ability of mammary cells to undergo 
normal morphogenesis; thereby preventing the formation of acini.
47
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Figure 5
Spyl inhibits acini formation and alters cellular morphology. Effects of Spyl 
over expression on the ability of HC11 cells to acquire a differentiated morphology was 
determined by culturing Cntl-HCl 1 and Spyl-HCl 1 stable cell lines to confluence and 
adding differentiation media. Upper panel depicts bright field images of confluent Cntl- 
HC11 or Spyl-HCl 1 cells at 40x magnification, lower panels depict cells following 
differentiation (40x magnification -  middle panel; lOOx magnification -  lower panel).
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Spyl overexpression induces precocious locular development in the virgin mammary 
gland in vivo
To investigate the effects of Spyl over expression in vivo we took advantage of 
the cleared fat pad transplant technique. During this technique the pre-pubertal inguinal 
mammary glands are cleared from the TEBs and the remaining fat pad is used as an 
injection site. The injected cells use the cleared mammary fat pad as an extra cellular 
matrix. To determine the effects of Spyl over expression on mammary gland 
morphogenesis in vivo we transplanted the stable Spyl-HCl 1 and Cntl-HCl 1 cells into 
the cleared fat pad of syngeneic mice (BALB/c). Carmine alum staining of the whole 
mounts from virgin transplanted mice demonstrated that fat-pads injected with Spyl- 
HCl 1 cells filled the mammary fat pad at a faster rate and exhibit increased ductal 
branching at only 8 weeks post-surgery (Figure 6A; right hand panels) in comparison to 
Cntl-HCl 1-transplanted fat pads (Figure 6A; left hand panels). At the end of puberty (10 
weeks) Cntl-HCl 1 fat pads were smooth and had small, regular spaced side branches 
(Figure 6B- left hand panels); however the Spyl-HCl 1 transplanted fat pads showed 
extensive alveolar development of the type that is normally associated with hormonal 
stimulation during pregnancy (Figure 6B; right hand panels).
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Figure 6
Spyl over expression induces precocious lobular development in the virgin 
mammary gland in vivo. Spyl-HCl 1 and Cntl-HCl 1 stable cells (0.5xl06 cells) were 
injected into the cleared fat pads of the 4th inguinal mammary glands of virgin, 22 day 
old syngenic BALB/c mice. Whole mounts of several transplanted glands were analyzed 
using carmine alum staining at different time points during puberty. (A) At 8 weeks post 
surgery, Spyl-HCl 1 cells fill the cleared mammary fat pads completely (right panel). At 
this stage of mammary gland development, Spyl-HCl 1 injected glands also demonstrate 
increased ductal branching in compare to Cntl-HCl 1 cells injected glands (left panel). 
(B) At 10 weeks post-transplantation Spyl-HCl 1 injected glands demonstrate enhanced 
alveolar development and increased ductal side branching (right panel); however Cntl- 
HCl 1 injected glands show regular spaced side branches (left panel).
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Spyl overexpression prevents lactogenesis in the mature mammary gland in vivo
During puberty, the rudimentary ductal network of quiescent epithelial cells in the 
immature mouse mammary gland rapidly proliferates in response to increased production 
of pubertal hormones and ductal morphogenesis occurs. During pregnancy, a second 
round of proliferation followed by differentiation induces alveolar morphogenesis to form 
the secretory epithelium responsible for milk production. To study the consequences of 
Spyl over expression on alveolar morphogenesis, whole mounts from two day lactating 
glands were examined. Whole mount staining of the two transplanted glands 
demonstrated that Cntl-HCl 1-injected fat pads had morphologically normal ductal and 
alveolar-like structures (Figure 7A). However, fat-pads injected with Spyl-HCl 1 cells 
demonstrated abnormal morphology; the luminal space was decreased substantially and 
the cells do not look fully differentiated. The alveolar space is not as big and open as it is 
in the wild type gland (Figure 7B).
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Figure 7
Spyl over expression prevents lactogenesis in the mature mammary gland in vivo. 
Spyl-HCl 1 and Cntl-HCl 1 stable cells (0.5xl06 cells) were injected into the cleared fat 
pads of the 4th inguinal mammary glands of virgin, 22 day old syngenic BALB/c mice. 
Whole mounts of 2 days lactating transplanted glands were analyzed after carmine alum 
staining at different magnifications. (A) Cntl-HCl 1 injected glands contain 
morphologically normal ductal and alveolar structures which represent the fully 
differentiated glands at lactating stage of mammary gland development. (B) Spyl-HCl 1 
injected glands demonstrate more condensed ductal structures and abnormal alveoli. 
Abnormal alveolar structures in these glands appear undifferentiated and lack organized 
acini.
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Spyl over expression induces mammary tumorigenesis in vivo
By 16 weeks post-transplantation significantly large tumors were visibly detected 
on the side of each mouse that had been transplanted with Spyl-HCl 1 cells, with no 
visible tumor occurring on the control gland side of the animal that had been transplanted 
with Cntl-HCl 1 cells (100% incidence; n=4) (Figure 8A). When dissected out all fat- 
pads injected with Spyl-HCl 1 cells were larger in size and had numerous large solid 
mammary tumors (Figure 8B; right hand panel), while all Cntl-HCl 1-injected fat pads 
were smaller and look completely normal with no visible outgrowths (Figure 8B; left 
hand panel). This is extremely exciting data, as the tumor incidence in virgin, young 
BALB/c mouse strain is known to be very low (Bult et al. 2000; Naf et al. 2002; Krupke 
et al. 2005; Begley et al. 2007). To gain statistical significance and to control for 
retrovirus random integration in genome, 22 more mammary fat-pad transplants using 4 
different Spyl-HCl 1 stable colonies have been performed and are awaiting analysis.
57
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Figure 8
Spyl over expression induces mammary tumorigenesis in vivo. Spyl-HCl 1 and 
Cntl-HCl 1 stable cells (0.5x106 cells) were injected into the cleared fat pads of the 4th 
inguinal mammary glands of virgin, 22 day old syngenic B ALB/c mice. (A) 16 weeks 
after the fat pad transplants, mammary glands injected with Spyl-HCl 1 cells produced 
large outgrowths; while the Cntl-HCl 1 glands looked normal. (B) Mammary glands were 
dissected and mammary tumors were observed only in Spyl-HCl 1 injected glands (left 
panel) Cntl-HCl 1 injected glands were smaller in size and did not represent any form of 
outgrowths (right panel).
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Estrogen stabilizes Spyl protein levels, but has no significant effect on Snvl mRNA 
We utilized the MCF7 cell line as a model system to study estrogen affects on 
Spyl protein and mRNA regulation. MCF7 cells are responsive to estrogen treatment as 
they express ER. In order to deplete the steroid hormones from MCF7 cells medium prior 
to the estrogen treatment, fetal calf serum was treated with charcoal. To activate the 
estrogen pathway, MCF7 cells were maintained in the medium supplemented with 
charcoal treated serum for 5 days and then treated with 10 nM estrogen as well as the 
vehicle control (DMSO) over the experimental time course. In order to inhibit the 
estrogen pathway, MCF7 cells were treated with 10 nM tamoxifen and the vehicle control 
(DMSO) over the same time course in the presence of estroid hormones (Osborne et al. 
1983; Sutherland et al. 1983a; Sutherland et al. 1983b). Our data shows that estrogen 
treatment cause abundance of Spyl at protein level and this effect is inhibited by 
tamoxifen, which is a specific estrogen pathway inhibitor (Figure 9A and 9B). 
Interestingly, estrogen treatment does not have a significant effect on Spyl mRNA level 
(Figure 9C). This data suggests that estrogen stabilizes Spyl protein levels. These 
findings are very important as we and others have shown that Spyl protein levels are 
elevated in many aggressive forms of cancer, including invasive ductal carcinoma of the 
breast (Zucchi et al. 2004) and breast cancer cell lines, but not normal cell lines (Figure 
10). Currently our group is studying Spyl protein stability after estrogen treatment using 
pulse chase analysis and we have initiated a large scale study on normal and cancerous 
breast tissues to compare both protein and mRNA levels of Spyl and possible signaling 
pathways.
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Figure 9
Estrogen treatment upregulates Spyl protein levels, but not Spyl mRNA levels. 
(A) MCF7 cells were cultured in charcoal treated media for 5 days and then treated with 
estrogen (E2) as described in materials and methods. Total protein extracts at different 
time points (Ohr, 3hr, 7hr, lOhr, 13hr, 26hr and 50hr) were analyzed by 10% SDS-PAGE 
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded 
in each lane as determined by Bradford protein assay and confirmed by immunoblotting 
the same blot with beta actin (lower panel). Spyl protein abundance is observed after 
estrogen (E2) treatment. (B) MCF7 cells were cultured and treated with TAM as 
described in materials and methods. Total protein extracts at different time points (Ohr, 
3/4hr, lhr, 3hr, 6hr, 9hr, 12hr, 24hr and 48hr) were analyzed by 10% SDS-PAGE 
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded 
in each lane as determined by Bradford protein assay and confirmed by immunoblotting 
the same blot with actin (lower panel). Spyl protein accumulation is not observed 
through out the treatment time course, after TAM treatment. (C) MCF7 cells were 
cultured in charcoal treated media for 5days and then treated with estrogen (E2) as 
described in materials and methods. Total mRNA extracts at various time points (Ohr,
3hr, 7hr, lOhr, 13hr, 26hr and 50hr) were analyzed by RT-PCR using random hexamer 
primers to generate first strand c-DNA followed by PCR using Spyl specific PCR 
primers (upper panel). Equal RNA was used in each RT-PCR reaction as determined by 
RNA nano assay and confirmed by equal GAPDH levels in all reactions (lower panel). 
Estrogen (E2) has no significant effect on Spyl mRNA levels.
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Figure 10
Spyl protein levels are elevated in breast cancer cell lines. MCF7 cells, HTB126 
cells and HTB125 cells were cultured in their specific growth media. Total protein 
extracts of three different proliferating cell lines were analyzed by 10% SDS-PAGE 
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded 
in each lane as determined by Bradford protein assay and confirmed by immunoblotting 
the same blot with actin (lower panel). Spyl protein abundance is clearly observed in 
cancerous cell lines (MCF7 and HTB126), but not in non cancerous cell line (HTB125).
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CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
Discussion and Future Directions
A more clear understanding of the processes regulating mammary gland 
development provides information about essential cellular decisions involved in normal 
growth, proliferation, migration, branching, invasion, differentiation and apoptosis. 
Elucidating these key pathways may provide insight to prevent, detect and treat different 
disorders, including proliferation disorders such as cancer. Recently, a SAGE analysis 
study revealed Spyl as one of the genes which is elevated in invasive ductal carcinoma of 
the breast (Zucchi et al. 2004). Our research supports these findings; we have 
demonstrated that Spyl protein levels are elevated in the cancerous cell lines in compare 
to non-cancerous cell lines and that Spyl expression is tightly regulated during normal 
mammary gland development at both protein and mRNA level. Importantly, we have 
demonstrated that Spyl levels are naturally elevated during proliferative stages of 
mammary gland development. Through the establishment of stable HC11 cell lines that 
overexpress Spyl, we have been able to study the consequences of Spyl overexpression 
on HC11 cell differentiation as well as mammary gland development. Using P-casein as a 
marker for mammary cell differentiation, we showed that Spyl overexpression 
suppresses HC11 cell differentiation in culture. To study different stage of mammary 
gland In vivo, we used mouse mammary gland cleared fat pad transplant technique. 
Different experiments on transplanted mice have revealed that Spyl overexpression 
increases the rate of ductal morphogenesis during puberty; however at the end of puberty 
Spyl-HCl 1 injected glands showed increased ductal side branching along with alveolar
65
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morphogenesis as compared to Cntl-HCl 1 injected glands. This data suggest that Spyl 
overexpression induces precocious lobular development in the virgin mammary gland in 
vivo as alveolar morphogenesis is known to be one of the mammary gland characteristics 
during pregnancy. Other studies have shown similar effects on mammary gland 
development when overexpressing ERa or down regulating p27 (Muraoka et al. 2001; 
Mallepell et al. 2006). Spyl is known to play a key role in the down regulation of p27 
(Porter et al. 2003), and this current work has implicated that Spyl expression may lay 
downstream of ERa stimulation (Figures 9 and 10).
In addition, using the HC11 stable cell lines both in vitro and in vivo assays have 
supported that the down regulation of Spyl protein levels is an essential event to support 
terminal differentiation and alveolar development of the mammary gland. Among 
different stage of mammary gland development, the final stage of alveolar morphogenesis 
(herein referred to as lactogenesis) was abrogated by constitutive Spyl overexpression. It 
is known that lactogenesis, as represented by a full term pregnancy, confers a significant 
protection against breast cancer when it occurs in the young animal or human (Kelsey 
and Gammon 1990). The fact that Spyl overexpression disrupts lactogenesis can further 
implicate Spyl in the initiation of carcinogenesis.
At approximately 16 weeks post-transplantation Spyl overexpressing glands 
displayed large solid tumors in 100% of mice transplanted to date (n=4). The importance 
of this data is compounded by the fact that tumor incidence in the young, virgin BALB/c 
mouse strain is known to be very low (Bult et al. 2000; Naf et al. 2002; Krupke et al. 
2005; Begley et al. 2007). This is the first evidence for a direct role for Spyl in 
tumorigenesis. More studies are required to determine statistical numbers with regard to
66
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the penetrance of Spyl in tumorigenesis. We have since performed 22 additionally fat- 
pad transplants using 4 different Spyl-HCl 1 stable colonies to gain statistical 
significance and also to control for retrovirus integration in the genome.
We have also investigated Spyl upstream signaling pathways during mammary 
gland development using the HC11 cell model system. Epidermal growth factor (EGF), 
one of the main components of the HC11 cell growth media and a component which is 
absent in the HC11 cell differentiation media, plays an essential role during development 
of this cell line. (Schroeder and Lee 1998; Sebastian et al. 1998) It is well established that 
EGF activates different signaling pathways such as the MAPK pathway (Boonstra et al. 
1995). Our data suggests that Spyl protein levels are regulated, at least in part, by the 
MAPK pathway as Spyl is downregulated after MAPK inhibition. Other studies have 
shown that Spyl induced oocyte maturation requires the activation of MAPK and 
injection of Spyl into oocytes results in the activation of the MAPK pathway 
(Lenormand et al. 1999). Collectively these data suggest a positive feedback loop 
between Spyl and the MAPK pathway. One of the known targets of MAPK pathway is c- 
Myc and c-Myc is known to be an important regulator of mammary gland development. 
(Alvarez et al. 1991; Liu et al. 1996) Expression of c-Myc promotes growth, neoplasia 
and apoptosis (Marcu et al. 1992; Ryan and Bimie 1996). Furthermore, abnormal c-Myc 
expression in the mammary gland results in formation of mammary tumors 
(Schoenenberger et al. 1988; Welm et al. 2005). c-Myc expression is tightly regulated in 
the mammary gland; it is up regulated during proliferation, apoptosis, and downregulated 
during differentiation (Ryan and Bimie 1996; Grolli et al. 1997). Interestingly, we have 
observed that expression of Spyl mimics the expression profile of c-Myc during
67
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mammary gland development. This correlation had provided the impetus for us to 
examine c-Myc as an upstream regulator for Spyl. We have determined that both Spyl 
protein and mRNA levels are elevated after c-Myc induction and this has suggested that 
c-Myc is indeed an upstream regulator for Spyl. This has stimulated the hypothesis that 
the regulatory effects of c-Myc on Spyl during mammary gland development and 
tumorogenesis occurs via activation of MAPK pathway; this link is currently something 
that we are investigating both in vitro and in vivo. We have further determined that up 
regulation of Spyl mRNA by c-Myc does not rely on de novo protein synthesis this 
suggests that c-Myc is functioning directly as a transcription factor for Spyl. We have 
analyzed the Spyl predicted promoter region for putative c-Myc binding sites and found 
c-Myc binding sites. Further study is required to definitely determine whether c-Myc is 
functioning to directly regulate the transcription of Spyl during mammary gland 
development. As mentioned previously, we and others have determined that Spyl protein 
levels are elevated in many aggressive forms of cancer, including invasive ductal 
carcinoma of the breast as well as many breast cancer cell lines (Zucchi et al. 2004). 
Using the breast cancerous cell line, MCF7 cells we have demonstrated that estrogen is 
capable of stabilizing Spyl protein levels; however this has no significant effect on Spyl 
mRNA levels. Currently our group is studying Spyl protein stability after estrogen 
treatment using pulse chase analysis and we have initiated a large scale study on normal 
and cancerous breast tissues to compare both protein and mRNA levels of Spyl and 
possible signaling pathways.
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MAPK mitogen activated protein kinase
MAPKKK MAP kinase kinase kinase
MEF mouse embryonic fibroblast
MPF maturation promoting factor
PBE Pumilio 2-Binding Elements
PKA protein kinase A
RINGO Rapid Inducer of G2/M Ooctye Maturation
S Synthesis
SAGE serial analysis of gene expression
ScpPirCP ubiquitin ligase pTrCP
SCFSkP2 Skp, Cullin, F-box containing complex
siRNA small interfering RNA
S/R Box Speedy/RINGO box
STAT signal transducers and activators of transcription
TAM tamoxifen
TEB terminal end bud
Thr threonine
Tyr tyrosine
X-RINGOsp X-RINGO small and processed 
X-Spyl Xenopus-SpyX
UPS ubiquitin proteasome system
UV ultraviolet irradiation
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